European Psychiatry - Volume 41 - April 2017

247 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S238–S302 S243
Conclusions There is a statistically significant cognitive decline in
patients with mild and moderate depression.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0402
Emotional schemas: A new cognitive
perspective for the distinction
between unipolar depression and
bipolar disorder
O. Onur
Istanbul Bakırköy Research and Training Hospital for psychiatry
neurology and ne, Psychiatry, Istanbul, Turkey
Introduction Clinicians need to make the differential diagnosis
between unipolar depression and bipolar disorder to guide their
treatment choices. Looking at the differences observed in the emo-
tional schemas might help with this differentiation. This study is
an exploratory investigation of schema theory’s Leahy’s emotional
schemas among individuals diagnosed with bipolar disorder and
unipolar depression.
Methods Three groups of subjects 56 unipolar depression in the
remission period, 70 bipolar eutimic and 58 healthy controls were
asked to fill out the Leahy Emotional Schema Scale (LESS). The
clinicians diagnosed the participants according to the criteria of
DSM-IV-TR with SCID-I, and rated the moods of the subjects with
the Beck Depression Scale, and the Young Mania Rating Scale
(YMRS). Statistical analyses were undertaken to identify the group
differences on LESS.
Results The bipolar eutimic and unipolar depression patients’
scores on the LESS dimensions were significantly different from the
healthy participants in the areas of control, consensus, acceptance
of feelings, dissimilarity and simplistic view of emotions.
Conclusions These results suggest that the metacognitive model
of unipolar depression might be extrapolated for patients with
bipolar disorder. Bipolar disorder may be associated with a general
activation of the emotional schemas.
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.
EW0403
Anxiety, stress and depression on
COPD patients. A qualitative research
E. Kotrotsiou ∗, E. Tzounis , Z. Daniil , C. Hatzoglou ,
N. Skenteris , K. Gourgoulianis
1 University of Applied Sciences of Thessaly, Nursing, Postgraduate
Program in Primary Health Care, Laboratory Science of Care, Larissa,
Greece
2 Primary National Health Network, Health Unit, Volos, Greece
3 University of Thessaly, Medicine, Larissa, Greece
4 University of Thessaly, Medicine, Postgraduate Program of Primary
Health Care, Larissa, Greece
∗ Corresponding author.
Introduction COPD is a common disease, has an impact not only
on psychical but also on psychological well-being. Anxiety, stress,
depression are common co-morbidities for COPD patients.
Objectives This paper proposes to study from a qualitative point
of view the effect of depression on COPD patients.
Aims A qualitative methodology was chosen in order to explore
75 (male n = 69, female n = 6) COPD patients’ symptoms and signs
of anxiety, stress and depression.
Methods Data were collected through semi-structured inter-
views. All patients also completed the Beck Inventory and the GDS
15 questionnaires. The interviews were conducted both in the gen-
eral university hospital of Larissa and in patients’ homes.
Results We enrolled 75 patients (15: normal, 17: mild depres-
sion, 7: moderate and 1 severe). Persistent low mood and lack
of interest was expressed by most of the participants. “Before I
get this thing, I was in a good mood, but not now”. Poor self-
management was associated with anxiety disorders and high
temper: “I withdrew, due to my health”. . .“I was really stressed,
and depressed, and quick-tempered”. COPD diagnosis was diffi-
cult for some patients: “At the beginning, I wasn’t in the mood for
anything, just sleeping and more of watching TV”. Other patients
seemed to be in a good mood: “I was never scared of anything, I am
happy”.
Conclusions This research shows that depressive and anxiety
symptoms are common among COPD patients. Depression has a
significant impact on the daily life of patients while breathlessness
made patients feel housebound and social isolated.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0404
Lurasidone for the treatment of major
depressive disorder with mixed
features: Do manic symptoms
moderate treatment response?
A. Pikalov ∗, J. Goldberg , Y. Mao , C. Siu , J. Tsai ,
J. Calabrese , A. Loebel
1 Sunovion Pharmaceuticals Inc., Global Medical Affairs, Fort Lee, USA
2 Icahn School of Medicine at Mount Sinai, Psychiatry, NY, USA
3 Sunovion Pharmaceuticals Inc., Medial Affairs, Fort Lee, USA
4 COS and Associates Ltd., Data Science, Hong Kong S.A.R.
5 UH Case Medical Center, Psychiatry, Cleveland, USA
∗ Corresponding author.
Background This post-hoc analysis evaluated whether the effi-
cacy of lurasidone in major depressive disorder (MDD) with mixed
features is moderated by the number and characteristics of manic
symptoms present at study baseline.
Methods Patients meeting DSM-IV-TR criteria for MDD who
presented with two or three manic symptoms (consistent with
the DSM–5 mixed features specifier) were randomly assigned
to 6 weeks of double-blind treatment with either lurasidone
20–60mg/d (n = 109) or placebo (n = 100). Finite mixture models
were applied to identify latent class patterns of the 10 baseline
manic symptoms.
Results Three latent class profiles were identified: 105 (50.5%)
patients had manic symptom profile 1 (MIX 1) with mean MADRS
33.0, mean YMRS 9.2, mean number of manic symptoms 3.8; 63
(30.3%) patients had manic symptom profile 2 (MIX 2) with similar
baseline mean MADRS (32.4) and YMRS (9.3) and lower number
of manic symptoms 3.5; 40 patients had manic symptom profile
3 (MIX 3) with significantly higher severity scores in MADRS (35)
and YMRS (14.9) and mean number of manic symptoms 4.6. A sig-
nificant moderating effect on change in YMRS score was observed
for the “decreased need for sleep” symptom, with greater lurasi-
done effect size (vs. Placebo) found in patients without vs. With
this symptom ( P< 0.05).
Conclusions In this post-hoc analysis of a placebo-controlled trial
involvingMDDpatientswithmixed features, absence of “decreased
need for sleep” was found to be significantly associated with
improvement in manic and depressive symptoms and to moderate
the treatment effect on manic symptoms.
Disclosure of interest I am full time employee of Sunovion phar-
maceuticals Inc.